Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: A systematic review

Journal of Oral Implantology

Volumn 39, Issue 4, 2013, Pages 510-520

  Chadha, Gurpreet K ^a   Ahmadieh, Azadeh ^a   Kumar, Satish ^a   Sedghizadeh, Parish P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bisphosphonates; Dental implants; Diphosphonates; Jaw; Oral; Osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

BONE REGENERATION; HUMAN; JAW OSTEONECROSIS; REVIEW; RISK ASSESSMENT; TOOTH IMPLANTATION;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DENTAL IMPLANTATION, ENDOSSEOUS; DIPHOSPHONATES; HUMANS; OSSEOINTEGRATION; RISK ASSESSMENT;

EID: 84883400679     PISSN: 01606972     EISSN: 15481336     Source Type: Journal    
DOI: 10.1563/AAID-JOI-D-11-00234     Document Type: Review

References (53)

1. Im GI, Qureshi SA, Kenny J, et al. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 2004;25: 4105-4115.
2. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002; 62: 6538-6544.
3. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000; 88: 2961-2978.
4. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18: 75-85.
5. Green J. Bisphosphonates: preclinical review. Oncologist. 2004;9: 3-13.
6. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65: 369-376.
7. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353: 99-102.
8. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91: 968-971.
9. Ruggiero SL, Mehrotra B. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med. 2004;351: 190-192.
10. Schwartz HC. Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg. 2004;62: 763-764.
11. Javed F, Romanos GE. Impact of diabetes mellitus and glycemic control on the osseointegration of dental implants. A systematic literature review. J Periodontol. 2009;80: 1719-1730.
12. Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants. 1995;10: 74-78.
13. Goss A, Bartold M, Sambrook P, et al. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series. J Oral Maxillofac Surg. 2010;68: 337-343.
14. Bedogni A, Bettini G, Totola A, et al. Oral bisphosphonateassociated osteonecrosis of the jaw after implant surgery: a case report and literature review. J Oral Maxillofac Surg. 2010;68: 1662-1666.
15. Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonaterelated osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg. 2010;68: 790-796.
16. Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res. 2009;20(suppl 4): 87-95.
17. Zahid T, Wang BY, Cohen R. Influence of bisphosphonates on alveolar bone loss around osseointegrated implants. J Oral Implantol. 2011;37: 335-346.
18. Koka S, Babu NM, Norell A. Survival of dental implants in post-menopausal bisphosphonate users. J Prosthodont Res. 2010; 54: 108-111.
19. Martin DC, O'Ryan FS, Indresano AT, et al. Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. J Oral Maxillofac Surg. 2010;68: 508-514.
20. Kasai T, Pogrel MA, Hossaini M. The prognosis for dental implants placed in patients taking oral bisphosphonates. J Calif Dent Assoc. 2009;37: 39-42.
21. Grant BT, Amenedo C, Freeman K, et al. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg. 2008;66: 223-230.
22. Bell BM, Bell RE. Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg. 2008;66: 1022-1024.
23. Fugazzotto PA, Lightfoot WS, Jaffin R, et al. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J Periodontol. 2007;78: 1664-1669.
24. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants. 2006;21: 349-353.
25. Favia G, Piattelli A, Sportelli P, Capodiferro S, Iezzi G. Osteonecrosis of the posterior mandible after implant insertion: a clinical and histological case report. Clin Implant Dent Relat Res. 2011;13: 58-63.
26. Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg. 2011;40: 277-284.
27. Narongroeknawin P, Danila MI, Humphreys LG Jr, Barasch A, Curtis J. Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist. 2010;30: 77-82.
28. Shin EY, Kwon YH, Herr Y, et al. Implant failure associated with oral bisphosphonate-related osteonecrosis of the jaw. J Periodontal Implant Sci. 2010;40: 90-95.
29. Park W, Kim NK, Kim MY, et al. Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporos Int. 2010;21: 527-533.
30. Shirota T, Nakamura A, Matsui Y, et al. Bisphosphonaterelated osteonecrosis of the jaw around dental implants in the maxilla: report of a case. Clin Oral Implants Res. 2009;20: 1402-1408.
31. Alons K, Kuijpers SC, de Jong E, et al. Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:e1-e7.
32. Brooks JK, Gilson AJ, Sindler AJ, et al. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103: 780-786.
33. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol. 2007;78: 584-594.
34. Ferlito S, Liardo C, Puzzo S. Bisphosphonates and dental implants: a case report and a brief review of literature. Minerva Stomatol. 2011;60: 75-81.
35. Garg A, Guez G. Study investigates novel approach to bone loss in the jaw. Dent Implantol Update. 2011;22: 9-15.
36. Fleisher KE, Glickman RS. Risk factors for bisphosphonaterelated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2011;69: 959.
37. Seymour RA, Walton G. Malignant disease and the delivery of dental care. Dent Update. 2010;37: 20-22, 25-26.
38. Koka S, Salinas TJ, Kennel KA. Osteoporosis, fracture risk, and prosthodontic implications. Int J Prosthodont. 2009;22: 505-506.
39. Montoya-Carralero JM, Parra-Mino P, Ramírez-Fernández P, et al. Dental implants in patients treated with oral bisphosphonates: a bibliographic review. Med Oral Patol Oral Cir Bucal. 2010;15: e65-e69.
40. Bourgeois SL Jr. Bisphosphonate medications - the good, the bad, and the ugly. Tex Dent J. 2009;126: 596-604.
41. Flichy-Fernández AJ, Balaguer-Martínez J, Peñarrocha- Diago M, Bagán JV. Bisphosphonates and dental implants: current problems. Med Oral Patol Oral Cir Bucal. 2009;14:E355-E360. Review.
42. McLeod NM. Oral bisphosphonates and dental implants. J Oral Maxillofac Surg. 2009;67:1355.
43. Pigrau C, Almirante B, Rodriguez D, et al. Osteomyelitis of the jaw: resistance to clindamycin in patients with prior antibiotics exposure. Eur J Clin Microbiol Infect Dis. 2009;28: 317-323.
44. Dai M, Li Y, Head TW, et al. Point of care. J Can Dent Assoc. 2008;74: 617-626.
45. Wynn RL. Do Fosamax-type drugs increase the risk of osteonecrosis of the jaw for patients receiving dental implants? Gen Dent. 2008;56: 410-411.
46. Phillips G. Bisphosphonate therapy and dental treatment. J Indiana Dent Assoc. 2007-2008;86(4): 4-8.
47. Otomo-Corgel J. Implants and oral bisphosphonates: risky business? J Periodontol. 2007;78: 373-376.
48. Garg A, Guez G. Study investigates novel approach to bone loss in the jaw. Dent Implantol Update. 2011;22: 9-15.
49. Garg AK. Bisphosphonates and avascular necrosis of alveolar bone: a potential threat to dental implants. Dent Implantol Update. 2006;17: 73-78.
50. Oliver R, Badr M. Interventions for the prevention of osteonecrosis of the jaws in patients receiving bisphosphonate therapy undergoing oral surgery (Protcol). Cochrane Database of Syst Reviews. 2010;2:CD008355.
51. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65: 415-423.
52. Sedghizadeh PP, Stanley K, Caliqiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc. 2009;140: 61-66.
53. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23: 826-836.